incPRINT as a platform for RNA-targeted drug discovery

Project description

Novel technology assists the discovery of RNA-targeting drugs

RNA molecules are master regulators of many biological processes, and emerging evidence underscores their role in disease. However, using small molecules to target RNA therapeutically has proven technologically challenging. To address this problem, scientists of the EU-funded incPRINT-DRUG project propose to use their high-throughput RNA–protein interaction technology designed to identify small molecules that target specific pathogenic RNA–protein complexes. This technology simultaneously assesses the efficacy, specificity and toxicity of drugs in living cells. The aim of the incPRINT-DRUG project is to adapt this tool for RNA drug discovery and contribute to the biomedical field.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• natural sciences › biological sciences › biochemistry › biomolecules › proteins
• medical and health sciences › clinical medicine › oncology
• natural sciences › biological sciences › genetics › RNA
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › antibiotic resistance

Programme(s)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme

Topic(s)

• ERC-2018-PoC - ERC Proof of Concept Grant

Call for proposal

ERC-2018-PoC

See other projects for this call

Funding Scheme

ERC-POC - Proof of Concept Grant

Host institution

INSTITUT CURIE

Net EU contribution

€ 150 000,00

Address

Rue D Ulm 26
75231 Paris
France

Region

Ile-de-France › Ile-de-France › Paris

Activity type

Research Organisations

Links

Other funding

€ 0,00

Beneficiaries (1)

INSTITUT CURIE

France

Net EU contribution

€ 150 000,00

Address

Rue D Ulm 26
75231 Paris

Region

Ile-de-France › Ile-de-France › Paris

Activity type

Research Organisations

Links

Other funding

€ 0,00